Literature DB >> 20306039

ALARA in rhTSH-stimulated post-surgical thyroid remnant ablation: what is the lowest reasonably achievable activity?

Daniele Barbaro, Frederik A Verburg, Markus Luster, Christoph Reiners, Domenico Rubello.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20306039     DOI： 10.1007/s00259-010-1402-8

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  22 in total

1.  Recombinant human thyroid-stimulating hormone is effective for radioiodine ablation of post-surgical thyroid remnants.

Authors:  Daniele Barbaro; Giuseppe Boni; Giuseppe Meucci; Umberto Simi; Paola Lapi; Paola Orsini; Cristina Pasquini; Anna Turco; Giuliano Mariani
Journal:  Nucl Med Commun       Date:  2006-08       Impact factor: 1.690

2.  Low iodine diet in I-131 ablation of thyroid remnants.

Authors:  H R Maxon; S R Thomas; A Boehringer; J Drilling; M I Sperling; J C Sparks; I W Chen
Journal:  Clin Nucl Med       Date:  1983-03       Impact factor: 7.794

3.  Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.

Authors:  Heribert Hänscheid; Michael Lassmann; Markus Luster; Stephen R Thomas; Furio Pacini; Claudia Ceccarelli; Paul W Ladenson; Richard L Wahl; Martin Schlumberger; Marcel Ricard; Al Driedger; Richard T Kloos; Steven I Sherman; Bryan R Haugen; Vincent Carriere; Carine Corone; Christoph Reiners
Journal:  J Nucl Med       Date:  2006-04       Impact factor: 10.057

4.  Low-activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients.

Authors:  M Chianelli; V Todino; F M Graziano; C Panunzi; D Pace; R Guglielmi; A Signore; E Papini
Journal:  Eur J Endocrinol       Date:  2008-12-12       Impact factor: 6.664

5.  rhTSH stimulation before radioiodine therapy in thyroid cancer reduces the effective half-life of (131)I.

Authors:  Christian Menzel; Wolfgang T Kranert; Natascha Döbert; Michaela Diehl; Thomas Fietz; Nadja Hamscho; Uwe Berner; Frank Grünwald
Journal:  J Nucl Med       Date:  2003-07       Impact factor: 10.057

6.  Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients.

Authors:  C S Bal; Ajay Kumar; G S Pant
Journal:  J Clin Endocrinol Metab       Date:  2004-04       Impact factor: 5.958

7.  Iodine excretion during stimulation with rhTSH in differentiated thyroid carcinoma.

Authors:  M Löffler; M Weckesser; C Franzius; P Kies; O Schober
Journal:  Nuklearmedizin       Date:  2003-12       Impact factor: 1.379

8.  Guidelines for radioiodine therapy of differentiated thyroid cancer.

Authors:  M Luster; S E Clarke; M Dietlein; M Lassmann; P Lind; W J G Oyen; J Tennvall; E Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10       Impact factor: 9.236

9.  Differentiated thyroid carcinoma: the new UICC 6th edition TNM classification system in a retrospective analysis of 169 patients.

Authors:  Natascha Döbert; Christian Menzel; Sabine Oeschger; Frank Grünwald
Journal:  Thyroid       Date:  2004-01       Impact factor: 6.568

10.  A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer.

Authors:  Tania Pilli; Ernesto Brianzoni; Francesca Capoccetti; Maria Grazia Castagna; Sara Fattori; Angela Poggiu; Gloria Rossi; Francesca Ferretti; Elisa Guarino; Luca Burroni; Angelo Vattimo; Claudia Cipri; Furio Pacini
Journal:  J Clin Endocrinol Metab       Date:  2007-07-03       Impact factor: 5.958
View more
  3 in total

1.  On the effectiveness of recombinant human TSH as a stimulating agent for 131I treatment of metastatic differentiated thyroid cancer.

Authors:  Paolo Zanotti-Fregonara; Elif Hindié
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-12       Impact factor: 9.236

2.  The absorbed dose to the blood is a better predictor of ablation success than the administered 131I activity in thyroid cancer patients.

Authors:  Frederik A Verburg; Michael Lassmann; Uwe Mäder; Markus Luster; Christoph Reiners; Heribert Hänscheid
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-01-06       Impact factor: 9.236

Review 3.  Personalized management of differentiated thyroid cancer in real life - practical guidance from a multidisciplinary panel of experts.

Authors:  Alfredo Campennì; Daniele Barbaro; Marco Guzzo; Francesca Capoccetti; Luca Giovanella
Journal:  Endocrine       Date:  2020-08-09       Impact factor: 3.633
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.